Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Eduardo Davila

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-0817
    Other Positions
    TitleDirector-Faculty
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-MED
    DivisionONC GENERAL OPERATIONS


    Collapse Research 
    Collapse research activities and funding
    R25CA291640     (DAVILA, EDUARDO V)Aug 1, 2025 - Jul 31, 2030
    NIH
    Students and Teachers Achieving Cancer Research Experiences Together (START) Program
    Role: Principal Investigator
    R01CA271537     (DAVILA, EDUARDO V)May 3, 2023 - Apr 30, 2028
    NIH
    Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity
    Role: Principal Investigator
    R25GM140243     (DAVILA, EDUARDO V)Feb 1, 2022 - Jan 31, 2027
    NIH
    Colorado Preparation in Interdisciplinary Knowledge to Excel PREP
    Role: Principal Investigator
    I01BX004935     (DAVILA, EDUARDO V)Apr 1, 2020 - Mar 31, 2025
    NIH
    Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity
    Role: Principal Investigator
    T32CA236734     (JIMENO, ANTONIO)Jul 8, 2019 - Jun 30, 2030
    NIH
    Cancer Immunotherapy and Experimental Therapeutics - T32
    Role: Co-Principal Investigator
    R01CA207913     (DAVILA, EDUARDO V)Apr 1, 2017 - Mar 31, 2022
    NIH
    Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition
    Role: Principal Investigator
    R25GM113262     (CAREY, GREGORY B)Mar 1, 2016 - Feb 28, 2026
    NIH
    UMB Postbaccalaureate Research Education Program
    Role: Co-Principal Investigator
    I01BX002142     (DAVILA, EDUARDO)Jan 1, 2015 - Dec 31, 2019
    NIH
    IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target
    Role: Principal Investigator
    R01CA166961     (RAPOPORT, AARON P)Sep 1, 2012 - Aug 31, 2017
    NIH
    Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
    Role: Co-Principal Investigator
    R01CA140917     (DAVILA, EDUARDO)Jun 1, 2009 - May 31, 2015
    NIH
    TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Albert GK, Cao P, Davila E. Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity. Front Immunol. 2025; 16:1617773. PMID: 40948803.
      View in: PubMed
    2. Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956. PMID: 40378054.
      View in: PubMed
    3. Patel V, Collins JW, Marescaux J, Dohler M, Saikali S, Dasgupta P, Reddy S, Gamal A, Patel E, Rogers T, Siddiqui A, Breda A, Mottrie A, Hassan A, Hung A, Secord A, Rocco B, Pugh C, Sundaram C, Sighinolfi MC, Ellison EC, Davila EP, Wilson E, Balkhy H, Kaouk J, Liang C, Kavoussi LR, Roche M, Martino M, Anvari M, Sylla P, Coelho RF, Thomas R, Clayman R, Leveillee R, Estape R, Goldberg R, Madder R, Horgan S, Magnuson JS, Nathan S, Ross S, Costello A, Xu Z, Chauhan S, Redan J, Satava R, Miles B, Sachdeva AK, Moschovas MC. International multispecialty consensus statement and expert opinion of best practices in telesurgery. J Robot Surg. 2025 Apr 01; 19(1):135. PMID: 40167848.
      View in: PubMed
    4. Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, Witkowski MT, Lucia MS, Schwartz MS, Pomfret EA, Mathes DW, Wang Z. Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood. 2025 Jan 30; 145(5):508-519. PMID: 39561285.
      View in: PubMed
    5. Sun Y, Yee E, Fujiwara Y, Dickinson K, Guo Y, Sun Z, Hu J, Davila E, Schulick RD, Zhu Y. CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors. J Immunother Cancer. 2025 Jan 13; 13(1). PMID: 39805660.
      View in: PubMed
    6. Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 Oct 22; 134(24). PMID: 39436696.
      View in: PubMed
    7. Haverkos B, Zain J, Kamdar M, Neuwelt A, Davila E, Bradeen X, Major A, Bair S, Jasem J, Smith C, Abbott D, Porcu P. Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial. Blood Adv. 2024 02 13; 8(3):708-711. PMID: 38150586.
      View in: PubMed
    8. Kent A, Crump LS, Davila E. Beyond a? T cells: NK, iNKT, and ?dT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML. Front Immunol. 2023; 14:1202950. PMID: 37654497.
      View in: PubMed
    9. Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219. PMID: 36378549.
      View in: PubMed
    10. Guo J, Kent A, Davila E. Chimeric non-antigen receptors in T cell-based cancer therapy. J Immunother Cancer. 2021 08; 9(8). PMID: 34344725.
      View in: PubMed
    11. Kent A, Longino NV, Christians A, Davila E. Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy. Front Immunol. 2021; 12:658611. PMID: 34012443.
      View in: PubMed
    12. Mar?n-Jim?nez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021; 12:607282. PMID: 33854497.
      View in: PubMed
    13. Younis RH, Ghita I, Elnaggar M, Chaisuparat R, Theofilou VI, Dyalram D, Ord RA, Davila E, Tallon LJ, Papadimitriou JC, Webb TJ, Bentzen SM, Lubek JE. Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. Front Immunol. 2021; 12:596646. PMID: 33776991.
      View in: PubMed
    14. Ciavattone NG, Wu L, O'Neill R, Qiu J, Davila E, Cao X. MyD88 Costimulation in Donor CD8+ T Cells Enhances the Graft-versus-Tumor Effect in Murine Hematopoietic Cell Transplantation. J Immunol. 2021 02 15; 206(4):892-903. PMID: 33408257.
      View in: PubMed
    15. Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020 09 08; 4(17):4256-4266. PMID: 32898250.
      View in: PubMed
    16. Geng D, Ciavattone N, Lasola JJ, Shrestha R, Sanchez A, Guo J, Vlk A, Younis R, Wang L, Brown AJ, Zhang Y, Velasco-Gonzalez C, Tan AC, Davila E. Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels. Commun Biol. 2020 06 12; 3(1):306. PMID: 32533049.
      View in: PubMed
    17. Guo J, Muse E, Christians AJ, Swanson SJ, Davila E. An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell-Based Cancer Vaccine. Cancer Immunol Res. 2019 09; 7(9):1523-1534. PMID: 31266784.
      View in: PubMed
    18. Suk Lee Y, Davila E, Zhang T, Milmoe HP, Vogel SN, Bromberg JS, Scalea JR. Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin. Innate Immun. 2019 01; 25(1):46-59. PMID: 30782043.
      View in: PubMed
    19. Scalea JR, Lee YS, Davila E, Bromberg JS. Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation. Transplantation. 2018 03; 102(3):359-367. PMID: 29189485.
      View in: PubMed
    20. Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MB, Miller CR, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF. Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma. Sci Rep. 2018 01 19; 8(1):1180. PMID: 29352201.
      View in: PubMed
    21. Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. Clin Cancer Res. 2018 01 01; 24(1):234-247. PMID: 29074603.
      View in: PubMed
    22. Kaczanowska S, Joseph AM, Guo J, Tsai AK, Lasola JJ, Younger K, Zhang Y, Gonzales CV, Davila E. A Synthetic CD8a:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. Cancer Res. 2017 12 15; 77(24):7049-7058. PMID: 29055013.
      View in: PubMed
    23. Tsai AK, Khan AY, Worgo CE, Wang LL, Liang Y, Davila E. A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. Cancer Immunol Res. 2017 09; 5(9):790-803. PMID: 28775208.
      View in: PubMed
    24. Roberts NB, Wadajkar AS, Winkles JA, Davila E, Kim AJ, Woodworth GF. Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma. Oncoimmunology. 2016; 5(9):e1208876. PMID: 27757301.
      View in: PubMed
    25. Joseph AM, Srivastava R, Zabaleta J, Davila E. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res. 2016 08; 4(8):708-16. PMID: 27267778.
      View in: PubMed
    26. Tsai AK, Davila E. Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. Oncoimmunology. 2016 May; 5(5):e1122158. PMID: 27467930.
      View in: PubMed
    27. Kaczanowska S, Davila E. Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells. Oncoimmunology. 2016 Apr; 5(4):e1076609. PMID: 27141375.
      View in: PubMed
    28. Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res. 2015 May 15; 75(10):1959-1971. PMID: 25795705.
      View in: PubMed
    29. Li Z, Younger K, Gartenhaus R, Joseph AM, Hu F, Baer MR, Brown P, Davila E. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest. 2015 Mar 02; 125(3):1081-97. PMID: 25642772.
      View in: PubMed
    30. Jain A, Kaczanowska S, Davila E. IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance. Front Immunol. 2014; 5:553. PMID: 25452754.
      View in: PubMed
    31. Song C, Sadashivaiah K, Furusawa A, Davila E, Tamada K, Banerjee A. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology. 2014 Jan 01; 3(1):e27680. PMID: 24790793.
      View in: PubMed
    32. Patrick K, Marshall SJ, Davila EP, Kolodziejczyk JK, Fowler JH, Calfas KJ, Huang JS, Rock CL, Griswold WG, Gupta A, Merchant G, Norman GJ, Raab F, Donohue MC, Fogg BJ, Robinson TN. Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART). Contemp Clin Trials. 2014 Jan; 37(1):10-8. PMID: 24215774.
      View in: PubMed
    33. So EC, Sallin MA, Zhang X, Chan SL, Sahni L, Schulze DH, Davila E, Strome SE, Jain A. A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity. J Immunol Methods. 2013 Aug 30; 394(1-2):40-8. PMID: 23680234.
      View in: PubMed
    34. Guha P, Kaptan E, Bandyopadhyaya G, Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV, Vasta GR, Ahmed H. Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci U S A. 2013 Mar 26; 110(13):5052-7. PMID: 23479624.
      View in: PubMed
    35. Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013 Jun; 93(6):847-63. PMID: 23475577.
      View in: PubMed
    36. Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, McKenna C, Bansal N, Ochoa A, Davila E. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 2012 Dec 01; 72(23):6209-16. PMID: 23041547.
      View in: PubMed
    37. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012 Dec 01; 18(23):6436-45. PMID: 23032741.
      View in: PubMed
    38. Sakoda Y, Park JJ, Zhao Y, Kuramasu A, Geng D, Liu Y, Davila E, Tamada K. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood. 2011 Feb 24; 117(8):2506-14. PMID: 21220749.
      View in: PubMed
    39. Geng D, Zheng L, Srivastava R, Velasco-Gonzalez C, Riker A, Markovic SN, Davila E. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res. 2010 Oct 01; 70(19):7442-54. PMID: 20807806.
      View in: PubMed
    40. Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C, Davila E. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood. 2010 Nov 04; 116(18):3494-504. PMID: 20696947.
      View in: PubMed
    41. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J. 2008 Oct; 22(10):3628-37. PMID: 18587008.
      View in: PubMed
    42. Zheng L, Asprodites N, Keene AH, Rodriguez P, Brown KD, Davila E. TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood. 2008 Mar 01; 111(5):2704-13. PMID: 18086870.
      View in: PubMed
    43. Davila E, Byrne GW, LaBreche PT, McGregor HC, Schwab AK, Davies WR, Rao VP, Oi K, Tazelaar HD, Logan JS, McGregor CG. T-cell responses during pig-to-primate xenotransplantation. Xenotransplantation. 2006 Jan; 13(1):31-40. PMID: 16497210.
      View in: PubMed
    44. Davila E, Kang YM, Park YW, Sawai H, He X, Pryshchep S, Goronzy JJ, Weyand CM. Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis. J Immunol. 2005 Jun 01; 174(11):7292-301. PMID: 15905576.
      View in: PubMed
    45. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003 Jun 15; 63(12):3281-8. PMID: 12810660.
      View in: PubMed
    46. Davila E, Velez MG, Heppelmann CJ, Celis E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood. 2002 Oct 01; 100(7):2537-45. PMID: 12239167.
      View in: PubMed
    Davila's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (278) concept(s)
    _
    Co-Authors Expand Description
    See all (40) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)